Literature DB >> 8796206

Gastric cancer.

P McCulloch1.   

Abstract

We are gaining a clearer insight into the causes and mechanisms of gastric carcinogenesis, and may be able to reduce the incidence in the future by Helicobacter pylori eradication, perhaps in conjunction with nutritional supplements. The work required to establish this kind of prevention programme still has a long way to go. Surveillance and early detection are a key area, and current hopes rest with an increasingly low threshold for gastroscopy together with improved awareness in both patients and general practitioners. Identification of a high-risk group for surveillance would be a major advance, and may become possible due to advances in molecular biology. In terms of treatment, surgery remains the mainstay, but for useful analysis of its' efficacy, uniform and detailed pathological staging is vital. Pre-operative assessment has improved greatly in recent years, resulting in fewer nontherapeutic laparotomies, thanks to a combination of improved imaging techniques and laparoscopy. Limited endoscopic surgery is now feasible for very early disease. The extent of radical surgery remains controversial: a strong argument can be made for concentrating this kind of surgery in the hands of a limited number of specialist units who will have the numbers and the expertise to answer the outstanding questions. Chemotherapy has yet to prove its value, but there are hopes that the newest regimes may do this. Treatment results in the West remain unsatisfactory, but they have improved in the last two decades, and should be capable of considerable further improvement.

Entities:  

Mesh:

Year:  1996        PMID: 8796206      PMCID: PMC2398528          DOI: 10.1136/pgmj.72.850.450

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  60 in total

1.  Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients.

Authors:  J J Bonenkamp; I Songun; J Hermans; M Sasako; K Welvaart; J T Plukker; P van Elk; H Obertop; D J Gouma; C W Taat
Journal:  Lancet       Date:  1995-03-25       Impact factor: 79.321

2.  Extensive versus limited lymph node dissection for gastric cancer: a comparative study of 320 patients.

Authors:  F Pacelli; G B Doglietto; R Bellantone; S Alfieri; A Sgadari; F Crucitti
Journal:  Br J Surg       Date:  1993-09       Impact factor: 6.939

3.  Gastric cancer: a curable disease in Britain.

Authors:  H M Sue-Ling; D Johnston; I G Martin; M F Dixon; M R Lansdown; M J McMahon; A T Axon
Journal:  BMJ       Date:  1993-09-04

4.  Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population.

Authors:  W J Blot; J Y Li; P R Taylor; W Guo; S Dawsey; G Q Wang; C S Yang; S F Zheng; M Gail; G Y Li
Journal:  J Natl Cancer Inst       Date:  1993-09-15       Impact factor: 13.506

5.  Factors influencing noncompliance and contamination in a randomized trial of "Western" (r1) versus "Japanese" (r2) type surgery in gastric cancer.

Authors:  T M Bunt; H J Bonenkamp; J Hermans; C J van de Velde; J W Arends; G Fleuren; J A Bruijn
Journal:  Cancer       Date:  1994-03-15       Impact factor: 6.860

6.  Goseki histological grading of gastric cancer is an important predictor of outcome.

Authors:  I G Martin; M F Dixon; H Sue-Ling; A T Axon; D Johnston
Journal:  Gut       Date:  1994-06       Impact factor: 23.059

7.  Comparison of the molecular genetics of c-erb-B2 and p53 expression in stomach cancer in Britain and Japan.

Authors:  P G McCulloch; A Ochiai; G M O'Dowd; J R Nash; M Sasako; S Hirohashi
Journal:  Cancer       Date:  1995-02-15       Impact factor: 6.860

8.  Preoperative assessment of gastric carcinoma: value of two-phase dynamic CT with mechanical iv. injection of contrast material.

Authors:  J S Cho; J K Kim; S M Rho; H Y Lee; H Y Jeong; C S Lee
Journal:  AJR Am J Roentgenol       Date:  1994-07       Impact factor: 3.959

9.  Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.

Authors:  H Nakazato; A Koike; S Saji; N Ogawa; J Sakamoto
Journal:  Lancet       Date:  1994-05-07       Impact factor: 79.321

10.  The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up.

Authors:  M T Hallissey; J A Dunn; L C Ward; W H Allum
Journal:  Lancet       Date:  1994-05-28       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.